Bollard Group LLC acquired a new position in shares of Prime Medicine, Inc. (NYSE:PRME – Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 361,136 shares of the company’s stock, valued at approximately $3,200,000. Bollard Group LLC owned approximately 0.37% of Prime […]
Shares of Prime Medicine, Inc. (NYSE:PRME – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the twelve analysts that are covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation and ten have assigned a buy recommendation to the company. The average 12-month price […]
Prime Medicine, Inc. (NYSE:PRME – Get Free Report) gapped down before the market opened on Wednesday . The stock had previously closed at $6.50, but opened at $6.27. Prime Medicine shares last traded at $6.12, with a volume of 160,501 shares traded. Wall Street Analysts Forecast Growth Several brokerages recently commented on PRME. Chardan Capital […]
Shares of Prime Medicine, Inc. (NYSE:PRME – Get Free Report) gapped up prior to trading on Tuesday . The stock had previously closed at $6.93, but opened at $7.26. Prime Medicine shares last traded at $6.73, with a volume of 117,359 shares traded. Analysts Set New Price Targets PRME has been the topic of several […]
HC Wainwright assumed coverage on shares of Prime Medicine (NYSE:PRME – Free Report) in a report published on Monday, Marketbeat reports. The firm issued a buy rating and a $10.00 price objective on the stock. HC Wainwright also issued estimates for Prime Medicine’s Q2 2024 earnings at ($0.40) EPS, Q3 2024 earnings at ($0.40) EPS, […]